Scroll

doxycycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives	961	564-25-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: doxycycline doxycycline hyclate doxycycline calcium doxycycline hydrochloride doxycycline hydrate doxycycline HCl acticlate	A synthetic tetracycline derivative with similar antimicrobial activity. Molecular weight: 444.44 Formula: C22H24N2O8 CLOGP: -0.98 LIPINSKI: 1 HAC: 10 HDO: 6 TPSA: 181.62 ALOGS: -2.85 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

doxycycline
doxycycline hyclate
doxycycline calcium
doxycycline hydrochloride
doxycycline hydrate
doxycycline HCl
acticlate

A synthetic tetracycline derivative with similar antimicrobial activity.

Molecular weight: 444.44
Formula: C22H24N2O8
CLOGP: -0.98
LIPINSKI: 1
HAC: 10
HDO: 6
TPSA: 181.62
ALOGS: -2.85
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	93 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.43 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
EoM (Fraction excreted unchanged in urine)	41 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.69 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.46 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.12 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 5, 1967	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abortion incomplete	2014.19	10.29	522	82535	2609	63403356
Drug hypersensitivity	1159.36	10.29	1707	81350	308980	63096985
Haemorrhage	912.89	10.29	705	82352	60317	63345648
Jarisch-Herxheimer reaction	277.40	10.29	70	82987	307	63405658
Pregnancy	201.82	10.29	245	82812	36591	63369374
Cholangitis sclerosing	193.69	10.29	75	82982	1566	63404399
Oesophageal ulcer	158.83	10.29	89	82968	4401	63401564
Endometritis	136.26	10.29	51	83006	967	63404998
Heavy menstrual bleeding	131.10	10.29	138	82919	17635	63388330
Gastrointestinal mucosal necrosis	122.54	10.29	24	83033	17	63405948

Showing 1 to 10 of 286 entries

Previous1 2 3 4 5…29Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Jarisch-Herxheimer reaction	755.41	11.24	166	38210	425	34918130
Gastrointestinal mucosal necrosis	133.99	11.24	33	38343	159	34918396
Rash	124.01	11.24	528	37848	222224	34696331
Drug hypersensitivity	115.83	11.24	266	38110	80263	34838292
Congenital hiatus hernia	115.33	11.24	41	38335	803	34917752
Photosensitivity reaction	99.78	11.24	87	38289	10507	34908048
Gastrointestinal injury	97.08	11.24	31	38345	430	34918125
Breath sounds abnormal	86.84	11.24	67	38309	6814	34911741
Drug ineffective for unapproved indication	81.97	11.24	115	38261	23600	34894955
Oesophageal ulcer	78.60	11.24	48	38328	3333	34915222

Showing 1 to 10 of 229 entries

Previous1 2 3 4 5…23Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abortion incomplete	2016.52	10.01	520	103561	2544	79637763
Drug hypersensitivity	1032.55	10.01	1584	102497	297332	79342975
Jarisch-Herxheimer reaction	913.98	10.01	219	103862	738	79639569
Haemorrhage	691.80	10.01	717	103364	90401	79549906
Cholangitis sclerosing	274.59	10.01	110	103971	2527	79637780
Pregnancy	258.93	10.01	241	103840	26610	79613697
Gastrointestinal mucosal necrosis	242.36	10.01	57	104024	173	79640134
Rash	174.66	10.01	1321	102760	577037	79063270
Oesophageal ulcer	160.90	10.01	105	103976	6870	79633437
Gastrointestinal injury	149.25	10.01	54	104027	929	79639378

Showing 1 to 10 of 400 entries

Previous1 2 3 4 5…40Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A01AB22	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	J01AA02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:38068	antimalarials
CHEBI has role	CHEBI:50846	Immunologic factor
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:176497	geroprotectors
FDA Chemical/Ingredient	N0000007948	Tetracyclines
FDA EPC	N0000175882	Tetracycline-class Drug
MeSH PA	D000900	Anti-Bacterial Agents

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Trachoma	indication	2576002	DOID:11265
Listeriosis	indication	4241002	DOID:11573
Inhalational anthrax	indication	11389007
Actinomycotic infection	indication	11817007	DOID:8478
Gonorrhea	indication	15628003	DOID:7551
Tularemia	indication	19265001
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Murine typhus	indication	25668000	DOID:11256
Granuloma inguinale	indication	28867007	DOID:9113

Showing 1 to 10 of 77 entries

Previous1 2 3 4 5…8Next

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Periodontal disease	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Doxirobe Gel	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.23	acidic
pKa2	7.13	acidic
pKa3	9.78	acidic
pKa4	11.26	acidic
pKa5	12.46	acidic
pKa6	13.08	acidic
pKa7	9.07	Basic

Showing 1 to 7 of 7 entries

Previous1Next

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	8394405	April 7, 2024	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	8394406	April 7, 2024	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	8470364	April 7, 2024	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	8709478	April 7, 2024	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	8206740	Dec. 24, 2025	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
40MG	ORACEA	GALDERMA LABS LP	N050805	May 26, 2006	RX	CAPSULE	ORAL	7749532	Dec. 19, 2027	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
EQ 120MG BASE	DORYX MPC	MAYNE PHARMA	N050795	May 20, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	9295652	Oct. 23, 2034	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
EQ 120MG BASE	DORYX MPC	MAYNE PHARMA	N050795	May 20, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	9446057	Dec. 23, 2034	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
EQ 60MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	DORYX MPC	MAYNE PHARMA	N050795	May 20, 2016	RX	TABLET, DELAYED RELEASE	ORAL	9295652	Oct. 23, 2034	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
EQ 60MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	DORYX MPC	MAYNE PHARMA	N050795	May 20, 2016	RX	TABLET, DELAYED RELEASE	ORAL	9446057	Dec. 23, 2034	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

Showing 1 to 10 of 10 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
72 kDa type IV collagenase	Enzyme	P08253	MMP2_HUMAN		IC50	4.62	CHEMBL
Stromelysin-1	Enzyme	P08254	MMP3_HUMAN		IC50	4.60	CHEMBL
Neutrophil collagenase	Enzyme	P22894	MMP8_HUMAN	INHIBITOR	IC50	4.60	IUPHAR
Collagenase 3	Enzyme	P45452	MMP13_HUMAN	INHIBITOR	IC50	4.40	CHEMBL
Matrilysin	Enzyme	P09237	MMP7_HUMAN	INHIBITOR	Kd	4.14	IUPHAR
50S ribosomal protein L10	Ribosomal protein		RL10_HALMA				WOMBAT-PK
Tetracycline resistance protein, class B	Transporter		TCR2_ECOLX		IC50	5.04	WOMBAT-PK
Zinc finger protein mex-5	Cytosolic other		MEX5_CAEEL		EC50	4.42	WOMBAT-PK

Showing 1 to 8 of 8 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
DXT	PDB_CHEM_ID
002748	NDDF
002749	NDDF
002750	NDDF
006525	NDDF
10504007	SNOMEDCT_US
10592-13-9	SECONDARY_CAS_RN
1543946	RXNORM
17086-28-1	SECONDARY_CAS_RN
21502	MMSL

Showing 1 to 10 of 41 entries

Previous1 2 3 4 5Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Doxycyclate Hyclate	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1481	CAPSULE	100 mg	ORAL	ANDA	25 sections
Doxycycline	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1327	CAPSULE	150 mg	ORAL	ANDA	28 sections
Doxycycline	HUMAN PRESCRIPTION DRUG LABEL	1	0143-2112	TABLET, COATED	100 mg	ORAL	ANDA	25 sections
Doxycycline	HUMAN PRESCRIPTION DRUG LABEL	1	0143-2112	TABLET, COATED	100 mg	ORAL	ANDA	25 sections
Doxycycline	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9381	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	15 sections
DOXYCYCLINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9855	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
DOXYCYCLINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9855	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
DOXYCYCLINE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9855	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
Doxycycline Hyclate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-3141	CAPSULE, GELATIN COATED	50 mg	ORAL	ANDA	23 sections
Doxycycline Hyclate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-3141	CAPSULE, GELATIN COATED	50 mg	ORAL	ANDA	23 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next